Intravitreal Triamcinolone with Transpupillary Thermal Therapy (TTT) for Subfoveal Choroidal Neovascularization in Age Related Macular Degeneration

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN74123635

Enrollment

200

Registered

2005-05-16

Start date

2004-02-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Age-Related Macular Degeneration (ARMD) not available for current therapies Eye Diseases Age-Related Macular Degeneration (ARMD)

Interventions

Complete ophthalmologic examination, treatment with TTT alone compared with treatment with TTT plus intravitreous Triamcinolone. Ophthalmologic control to verify closure of CNV or re-treatment.

Eligibility

Inclusion criteria

Inclusion criteria: Patients with severe ARMD (choroidal neovascularization [CNV]) that could not be treated with photodynamic therapy (PDT) because of bad prognosis or economical reasons.

Exclusion criteria

Exclusion criteria: 1. Any patient that has indication for PDT and has the economical means to get this therapy 2. Media opacity 3. Previous treatment for CNV

Design outcomes

Primary

Measure	Time frame
Preservation of visual acuity	—

Secondary

Measure	Time frame
Closure of CNV, OCT characteristics	—

Countries

Mexico

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026